drugset / Trial / NCT00950196

Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia

NCT00950196

Phase 4 Completed 30 enrolled Sheba Medical Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Ataxia-Telangiectasia A-T is a neurodegenerative disorder of the cerebellum, manifesting with ataxia, as well as extrapyramidal features. Treatment of A-T is discouraging, since no treatment seems to change the course of disease, but improvement can be achieved by symptomatic treatment of the bothersome movement disorder . While various dopaminergic agents are occasionally used, reports of benefit are rather sparse and anecdotal. Amantadine, a well known drug used in influenza as well as movement disorder of Parkinson, has been proved to improve various other types of movement disorder as ataxia, chorea, dystonia, akinesia and attention span. The purpose of this study is to investigate weather amantadine sulphate improves ataxia and the movement disorder (bradykinesia, parkinsonism, dystonia, chorea), as well as the general well being in patients with A-T.

Timeline

Start
2008-11
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Amantadine Unknown 5 mg/kg
Subject Amantadine Unknown 8 mg/kg